• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by CareDx Inc.

    4/25/25 9:06:14 PM ET
    $CDNA
    Medical Specialities
    Health Care
    Get the next $CDNA alert in real time by email
    DEFA14A 1 caredx-2025definitiveaddit.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    Filed by the Registrant x Filed by a Party other than the Registrant o
    Check the appropriate box:
    oPreliminary Proxy Statement
    oConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    oDefinitive Proxy Statement
    xDefinitive Additional Materials
    oSoliciting Material under §240.14a-12
    CareDx, Inc.
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    xNo fee required.
    oFee paid previously with preliminary materials.
    oFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



















    proxynotice_additionalmate.jpg






    proxynotice_additionalmatea.jpg


    Get the next $CDNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDNA

    DatePrice TargetRatingAnalyst
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$28.00Underweight
    Wells Fargo
    8/19/2024$40.00Neutral → Buy
    BTIG Research
    5/13/2024Outperform → Mkt Perform
    Raymond James
    5/1/2024$15.00Hold → Buy
    Craig Hallum
    11/9/2023$10.00Equal-Weight → Overweight
    Stephens
    8/15/2023$12.00Mkt Perform → Outperform
    Raymond James
    5/11/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $CDNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Maag Peter sold $192,420 worth of shares (10,000 units at $19.24), decreasing direct ownership by 3% to 318,846 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      6/20/25 4:30:13 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Director Goldberg Michael was granted 12,103 shares, increasing direct ownership by 9% to 152,998 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      6/17/25 4:56:07 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Director Cohen Fred E was granted 12,103 shares, increasing direct ownership by 8% to 155,265 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      6/17/25 4:35:09 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    SEC Filings

    See more
    • CareDx Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CareDx, Inc. (0001217234) (Filer)

      6/12/25 4:32:37 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by CareDx Inc.

      144 - CareDx, Inc. (0001217234) (Subject)

      6/11/25 4:20:36 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - CareDx, Inc. (0001217234) (Filer)

      6/3/25 4:30:13 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Leadership Updates

    Live Leadership Updates

    See more
    • CareDx Appoints Jing Huang Chief Data and AI Officer

      CareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Company's long-term strategic growth plan. CareDx intends to share its long-term growth strategy during an Investor Day on October 15, 2024. Huang is a recognized leader in data science and machine learning, bringing to CareDx a proven trac

      10/9/24 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer

      CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024. Keith Kennedy brings more than 20 years of experience and e

      9/12/24 7:01:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Appoints John W. Hanna as its New President and Chief Executive Officer

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. "John is an outstanding leader with a proven track record of building high-performing teams that deliver consistent results. With extensive experience in the molecular diagnostics and life sciences tools industries, John is the right executive to bring strategic leadership to CareDx to propel the compan

      4/16/24 4:02:00 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/14/24 5:13:57 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/8/24 2:34:10 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/5/24 6:07:26 AM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Financials

    Live finance-specific insights

    See more
    • CareDx to Report First Quarter 2025 Financial Results

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please

      4/8/25 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx to Report Fourth Quarter and Full Year 2024 Financial Results

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to

      2/11/25 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports Preliminary Financial Results for Third Quarter 2024

      Third Quarter 2024 Financial Results to be Reported on November 4, 2024 CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Third quarter revenue is expected to be in the range of $82 million to $83 million, an increase of approximately 23% year-over-year. Grew Testing Services volume to approximately 44,600, an increase of approximately 16% year-over-year. Testi

      10/15/24 6:00:00 AM ET
      $CDNA
      Medical Specialities
      Health Care